Investigating how RAS proteins contribute to cancer through their movement in cells
Differential function and tumor vulnerabilities revealed by RAS membrane trafficking
This study is looking at how certain cancer-causing proteins called RAS interact with cell membranes, hoping to find new ways to block their harmful effects and improve cancer treatments for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10920382 on NIH RePORTER |
What this research studies
This research focuses on understanding how mutant RAS proteins, which are known to drive cancer, interact with cellular membranes. By studying the post-translational modifications that allow RAS to associate with these membranes, the research aims to identify new ways to inhibit RAS function in cancer cells. The approach includes advanced techniques like CRISPR screens to explore the differences in behavior between various RAS protein variants. Patients may benefit from insights that could lead to more effective cancer treatments targeting RAS.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers driven by mutant RAS genes, such as pancreatic, colorectal, or lung cancers.
Not a fit: Patients with cancers not associated with RAS mutations or those with early-stage cancers may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that more effectively target and inhibit RAS-driven cancers.
How similar studies have performed: Previous research has shown promise in targeting RAS proteins, but this specific approach focusing on membrane trafficking is relatively novel.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Philips, Mark Reid — New York University School of Medicine
- Study coordinator: Philips, Mark Reid
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.